Baylis Medical Opens MedTech Facility in Costa Rica

Baylis Medical is a Canadian company and leader in the development and commercialization of innovative medical devices in cardiology. Today the company announced its arrival in Costa Rica.

Costa Rica is committed to strengthening our productive sectors with high added value, via products and services that revolutionize the market while simultaneously generating quality formal employment – jobs with lasting roots and consistent opportunities for growth.

“With the opening of the Baylis Medical, the country, once again, focuses its trajectory for growth and innovation on the medical device industry. We are very proud that Baylis Medical has put its trust in Costa Rica to launch such an important plant, which will serve international markets through a strategic and transformative vision. We are very enthusiastic about this news and, from all of us at the Ministry of Foreign Trade, we wish Baylis Medical the greatest success,” commented Andrés Valenciano, Costa Rican Minister of Foreign Trade.

“We are proud to be expanding Baylis Medical with a new facility in Costa Rica. Our team in Costa Rica will be instrumental in helping us serve patients through leading cardiology devices that will improve the lives of people around the world for years to come,” said Kris Shah, President of Baylis Medical.

Jorge Sequeira, CINDE’s managing director, commented, “Thanks to its acknowledged track record in life sciences, the country has 12 of the world’s 30 leading medical firms. Today, Baylis Medical joins the cluster, which by the end of 2020 consisted of 81 companies and generated an accumulated total of more than 38,000 jobs in Costa Rica. Investing with purpose is taking on greater relevance for industry leaders and the country continues to lead in investment destinations noted for human talent, target market proximity, and supplier availability, based on extremely innovative concepts of sustainable production.”

Baylis Medical highlighted Costa Rica’swell-established medical device manufacturing sector, and its highly skilled workforce for its investment decision. In terms of core values, Costa Rica’s similarities to Canada made the country attractive for its expansion.

People interested in applying for one of the company’s positions may do so at costarica@baylismedical.com. The company is currently looking for a core team that will support the operation setup. It searches for passionate, energetic, and team-oriented staff. In the new year, Baylis Medical will begin building a team of manufacturing employees to support production of its world-leading cardiology devices.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”